Posts for Ticker ‘PCYC’

Top Analyst Upgrades & Downgrades (COF, CAT, CERN, CHKP, MOT, PCYC, POT, SNDK, TTWO, URBN, WMT)

These are this morning’s top analyst upgrades, downgrades, and initiations seen from Wall Street research calls:

Capital One Financial (NYSE: COF) Raised to Buy at SunTrust.
Caterpillar Inc. (NYSE: CAT) Raised to Outperform at Wells Fargo (late Thursday).
Cerner (NASDAQ: CERN) Started as Neutral at UBS.
Check Point Software (NASDAQ: CHKP) Cut to Hold at Stifel Nicolaus.
Motorola (NYSE: MOT) Cut to Neutral at Macquarie.
Pharmacyclics (NASDAQ: PCYC) Started as Buy at Merriman Curhan Ford.
Potash Corp (NYSE: POT) has seen target cuts at TD, Canaccord, Genuity, and BMO.
SanDisk Corp. (NASDAQ: SNDK) Raised to Neutral at JPMorgan.
Take-Two Interactive (NASDAQ: TTWO) Raised to Buy at Morgan Joseph.
Urban Outfitters (NASDAQ: URBN) Raised to Outperform at FBR.
Wal-Mart Stores (NYSE: WMT) Raised to Buy and $60 target at Goldman Sachs.

You are invited to join our free daily email distribution list to hear about top analyst upgrades and downgrades, IPOs and secondary offerings, ongoing day trader and options trader alerts, stock and market rumors, Buffett and guru investor news, M&A and more.

JON C. OGG

Posted on: January 29, 2010 – 8:32 am in Analyst Calls, , , , , , , , , , ,

BioHealth Business Daily (BMRN, DVAX, SEPR, STEM, PCYC, OCLS)

biotech imageToday is an unusually active day for many emerging biotech stocks in the news and we are seeing significant moves in response. We have more detail on each with appropriate links through to more analysis and data at BioHealthInvestor.com or VSInvestor.com:

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is seeing exponential trading volume in stock and options after a 10% rise today.

Dynavax Technologies Corporation (NASDAQ: DVAX) is up over 50%after the FDA removed a clinical hold on its hepatitis treatment.

The fight over the Sepracor, Inc. (NASDAQ: SEPR) acquisition has now gone to the level of a class action status.  We noted the very low P/E and multiple valuations yesterday on this one.

StemCells, Inc. (NASDAQ: STEM) traded slightly higher on word that it will soon begin a study with the University of California, San Francisco Children’s Hospital using purified human neural stem cells as a possible treatment for Pelizaeus-Merzbacher Disease.

Pharmacyclics Inc. (NASDAQ: PCYC) was trading up on news that its right offering is oversubscribed.

Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) is trading higher on report that it has been assigned a Medicare HCPCS code for its recently introduced Microcyn Skin & Wound HydroGel.

JON C. OGG
SEPTEMBER 10, 2009

Posted on: September 10, 2009 – 1:38 pm in Biotech, Drug companies, HI/LOW, Trading Alert, , , , , ,

Weekend of Cancer Data at AACR Ahead of ASCO (ALTH, AMGN, ARIA, ARRY, AZN, BIIB, CELG, CRIS, IMMU, IMGN, INFI, MEDX, MNTA, ONCY, PFE, PCYC, SUPG, TELK, THLD)

This weekend will be a potentially important oncology and cancer news weekend for drug and biotech stocks.  The American Association for Cancer Research Meeting will actually have a 100th annual meeting, and some traders and investors may be using this as a preview for what lies ahead at the American Society of Clinical Oncology (ASCO) annual meeting in a month.  The following companies which are presenting data:

  • Allos Therapeutics, Inc. (NASDAQ: ALTH)
  • Amgen (NASDAQ: AMGN)
  • ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)
  • Array BioPharma, Inc. (NASDAQ: ARRY)
  • AstraZeneca’s (NYSE: AZN) Medimmune unit
  • Biogen Idec Inc. (NASDAQ: BIIB)
  • Celgene Corporation (NASDAQ: CELG)
  • Curis, Inc. (NASDAQ: CRIS)
  • Immunomedics, Inc. (Nasdaq: IMMU)
  • ImmunoGen, Inc. (Nasdaq: IMGN)
  • Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)
  • Medarex, Inc. (Nasdaq: MEDX)
  • Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA)
  • Oncolytics Biotech, Inc. (NASDAQ: ONCY)
  • Pfizer (NYSE: PFE)
  • Pharmacyclics, Inc. (NASDAQ: PCYC)
  • SuperGen Inc. (NASDAQ:SUPG)
  • Telik, Inc. (Nasdaq: TELK)
  • Threshold Pharmaceuticals, Inc. (Nasdaq: THLD)

You can see a full summary of the data being presented at BioHealthInvestor.com site.  There will be others presenting data this weekend, and these were from the press releases of the meeting ahead of time.

JON C. OGG

Posted on: April 17, 2009 – 2:05 pm in Biotech, Calendar, Drug companies, , , , , , , , , , , , , , , , , , ,

Top Pre-Market Analyst Upgrades (CBT, PCYC, THX, X, UTX)

These are some of the top analyst upgrades and positive calls we are seeing this Wednesday morning:

  • Cabot Corp. (CBT) Raised to Buy at KeyBanc.
  • Pharmacyclics (PCYC) Raised to Outperform at RBC.
  • Tenet Healthcare (THC) Raised to Buy at Deutsche Bank.
  • U.S. Steel (X) Raised to Outperform at CIBC.
  • United Tech (UTX) Raised to Buy at UBS.

Jon C. Ogg
September 3, 2008

Posted on: September 3, 2008 – 7:09 am in Analyst Calls, , , , ,

The Week’s Top Biotech Movers For Next Week (TRCA, ACOR, ISPH, ONCY, PCYC, SQNM, IDEV, LGND, AUXL)

Out of the daily movers this last week, many of the top winners and losers were from news in many of the smaller biotech stocks.  We prepared a list of the winners and sinners from our daily review at BioHealthInvestor.com and gave a summary regarding the moves on each.  It is becoming more obvious that many small and mid-sized biotechs are going to be gobbled up by European or Asian biotech and pharma companies seeking the dollar-discount right now.

For starters, we ran a summary of the key moving pieces out of the American Society of Clinical Oncology (ASCO).  No review would be complete without it. Stocks covered: (AVAN, PFE, CELG, IMCL, DNA)

ACQUISITION NEWS
Tercica, Inc. (NASDAQ: TRCA) bites the dust as its own company the latest small cap biotech received a huge premium acquisition from a foreign buyer, with a 104% premium.  FULL DETAILS

MAJOR WINNERS
Acorda Therapeutics Inc. (NASDAQ: ACOR) had a great week after it announced positive data from a second Phase III study of its Fampridine-SR for patients’ walking abilities in MS patients.  FULL DETAILS

Inspire Pharmaceuticals Inc. (NASDAQ: ISPH) surged after reaching its primary endpoint in Phase III trial of Denufosol for Cystic Fibrosis.  FULL DETAILS

Oncolytics Biotech Inc. (NASDAQ: ONCY) gained after the Canadian biotech’s positive Phase II studies of intravenous REOLYSIN® in patients with sarcomas metastatic to the lung.  FULL DETAILS

Pharmacyclics Inc. (NASDAQ: PCYC) gained after its Phase 1/2 trial of motexafin gadolinium plus antibody targeted radiation therapy showed a high complete response rate in patients with non-Hodgkin’s lymphoma.  FULL DETAILS

Sequenom Inc. (NASDAQ: SQNM) surged after it announced its progress with a non-invasive technology that detects Down syndrome. FULL DETAILS

MAJOR LOSERS
Indevus Pharmaceuticals Inc. (NASDAQ: IDEV) tanked after an FDA request should cause a two-year delay in approving NEBIDO.  FULL DETAILS

MIXED REVIEW
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is one we gave a full pro and con review covering the upside of the stock and the negative side of the stock.  FULL DETAILS

Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL) was a strange stock this week.  The company reported great news but shares slid before the market figured out it had misinterpreted news in the company.  INITIAL DETAILS

Jon C. Ogg
June 7, 2008

Posted on: June 7, 2008 – 6:01 am in Biotech, The Week, , , , , , , , ,